Lusutrombopag (BioDeep_00000229534)

   

human metabolite


代谢物信息卡片


(2E)-3-{2,6-dichloro-4-[(4-{3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid

化学式: C29H32Cl2N2O5S (590.1408882)
中文名称: 卢曲波帕
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl
InChI: InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1

描述信息

B - Blood and blood forming organs > B02 - Antihemorrhagics > B02B - Vitamin k and other hemostatics
C78275 - Agent Affecting Blood or Body Fluid

同义名列表

3 个代谢物同义名

(2E)-3-{2,6-dichloro-4-[(4-{3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid; Lusutrombopag; Mulpleta



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Tomoyuki Kawachi, Mizuki Ninomiya, Takayuki Katsube, Toshihiro Wajima, Takushi Kanazu. Human mass balance, metabolism, and cytochrome P450 phenotyping of lusutrombopag. Xenobiotica; the fate of foreign compounds in biological systems. 2021 Mar; 51(3):287-296. doi: 10.1080/00498254.2020.1845416. [PMID: 33125290]
  • Hirohito Takeuchi, Yoshihiro Furuichi, Yu Yoshimasu, Yoshitaka Kasai, Masakazu Abe, Katsutoshi Sugimoto, Takao Itoi. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2021 Jan; 87(6):325-333. doi: 10.1272/jnms.jnms.2020_87-603. [PMID: 32238734]
  • Takayuki Katsube, Yuji Inoue, Takahiro Fukuhara, Takeshi Kano, Toshihiro Wajima. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. European journal of clinical pharmacology. 2020 Dec; 76(12):1659-1665. doi: 10.1007/s00228-020-02960-7. [PMID: 32666123]
  • Takayuki Katsube, Ryosuke Shimizu, Takahiro Fukuhara, Takeshi Kano, Toshihiro Wajima. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Clinical pharmacokinetics. 2019 11; 58(11):1469-1482. doi: 10.1007/s40262-019-00770-4. [PMID: 31055790]
  • Takayuki Katsube, Toshihiro Wajima, Takahiro Fukuhara, Takeshi Kano. Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist. Clinical therapeutics. 2019 09; 41(9):1747-1754.e2. doi: 10.1016/j.clinthera.2019.06.004. [PMID: 31303281]
  • Takayuki Katsube, Toru Ishibashi, Takeshi Kano, Toshihiro Wajima. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. Clinical pharmacokinetics. 2016 11; 55(11):1423-1433. doi: 10.1007/s40262-016-0411-6. [PMID: 27209291]
  • C Ponticelli. [Problems connected with kidney transplantation. Experiences at the Transplantation Center in Milan. Clinical selection of the recipient]. Minerva chirurgica. 1975 Aug; 30(15-16):854-7. doi: NULL. [PMID: 4745]